Navigation Links
Good news: Fewer maternal and child deaths
Date:6/12/2012

Since 1990, annual maternal deaths have declined by almost one half and the deaths of young children have declined from 12 million to 7.6 million in 2010.

Some of the world's poorest countries have achieved spectacular progress in reducing child deaths. Rates of child mortality in many African countries have been dropping twice as fast in recent years as during the 1990s. In Botswana, Egypt, Liberia, Madagascar, Malawi, Rwanda and the United Republic of Tanzania, the rate of decline was on average 5 percent or more a year between 2000 and 2010.

Similar progress has been seen in reducing maternal deaths, although in fewer developing countries: Equatorial Guinea, Nepal, and Vietnam have each cut maternal deaths by 75 percent.

But all the news is not good. Every two minutes, somewhere in the world, a woman dies from complications of pregnancy and her newborn baby's chances of survival are very poor. For every woman who dies, an additional 20-30 suffer significant and sometimes lifelong problems, as a result of their pregnancy.

In these same two minutes nearly 30 young children die of disease and illness that could have been prevented or effectively treated.

Many countries, especially in Africa and South Asia, are not making progress. Of the 75 countries with the highest burden of maternal and child mortality, 25 have made insufficient or no progress in reducing maternal deaths and 13 show no progress in reducing the number of young children who die.

"Global efforts to save the lives of women, newborn babies and young children are not moving fast enough," says Mickey Chopra, M.D., PhD., chief health officer of United Nation's Children's Fund (UNICEF) and co-chair of the Countdown to 2015 initiative. "Some countries are showing us what success looks like, but many other countries still have to learn the lessons of those successes."

Progress on maternal, newborn and child health, in the 75 highest-burden co
'/>"/>

Contact: Marshall Hoffman
marshall@hoffmanpr.com
703-533-353-51703
Hoffman & Hoffman Worldwide
Source:Eurekalert  

Page: 1 2 3 4 5 6 7

Related biology news :

1. Less couch time equals fewer cookies
2. Identification of differential proteins in maternal serum with Down syndrome
3. Should we play hide-and-go-seek with our childrens vegetables?
4. Studies reveal structure of EV71, a virus causing childhood illnesses
5. New study compares diets for weight management in obese children
6. Researchers unravel genetic mechanism of fatty liver disease in obese children
7. Genetic abnormality offers diagnostic hope for childrens cancer
8. How many calories does it take to reach childhood obesity prevention goals?
9. Zip code as important as genetic code in childhood obesity
10. Prenatal exposure to air pollution linked to childhood obesity
11. What is really causing the child obesity epidemic?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Good news: Fewer maternal and child deaths
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... , This release is available in German ... ( Melolontha melolontha ), the European forest cockchafer ( Melolontha ... genus. These insects can damage huge areas of broadleaf trees ... in their guts that help them to digest their woody ...
... (Spain) have mixed waste from the paper industry with ceramic ... brick that has low thermal conductivity meaning it acts as ... "The use of paper industry waste could bring ... considered as waste can be reused as raw material." ...
... University, Finland, have succeeded in organising virus ... materials. These nanomaterials studied by the Finnish ... sensing, optics, electronics and drug delivery. ... nanoparticles have been extensively studied in recent ...
Cached Biology News:Not without my microbes 2Not without my microbes 3Paper waste used to make bricks 2
(Date:7/30/2015)... -- AACC welcomed thousands of medical professionals and ... & Clinical Lab Expo in Atlanta ... revolutionary advancements in clinical testing technology and research ... diagnose patients quickly and accurately and make sure ... As of Wednesday, July 29, more than 17,500 ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Inc. (Nasdaq: OPTR ) announced that additional ... of fidaxomicin in patients with Clostridium difficile ... A. Miller, M.D., at the Digestive Disease Week 2009 ... http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , The additional data presented ...
... 2 Document sharing inefficiencies in clinical trials cost investigative ... recent online poll by IntraLinks(R), the leading provider of critical ... document-related administrative duties and repetitive requests for information as significant ... of the polling results include: , , ...
... (Nasdaq: NEOG ) announced today that its Scotland-based ... government to research China-specific food safety and plant health issues. ... laboratory in Beijing. Testing methods and data developed in this ... throughout China. , , "This agreement represents a great ...
Cached Biology Technology:Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Document Management Inefficiencies Cost Clinical Study Sites Time, Money 2Neogen Partners With Chinese Government 2
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
...
... long and outstanding history in the ... ago we became aware that our ... modified to inject Xenopus oocytes. We ... microdispenser to eliminate any tip movement ...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Biology Products: